Baseline characteristics
| Characteristics . | Value: n, median (range), or n (%) . |
|---|---|
| Total | n = 95 |
| Age | 70 (24-89) |
| ≥65 y | 61 (64) |
| ≥75 y | 31 (33) |
| Sex | |
| Female | 40 (42) |
| Male | 55 (58) |
| Ethnic origin | |
| Asian | 1 (1) |
| Black or African American | 5 (5) |
| Caucasian | 88 (92) |
| Not reported | 1 (1) |
| Prior AML therapies | 3 (0-8) |
| 1 | 17 (18) |
| 2 | 19 (20) |
| 3 | 22 (23) |
| ≥4 | 30 (32) |
| 0* | 7 (7) |
| ECOG performance status | |
| 0 | 26 (27) |
| 1 | 69 (73) |
| ELN classification | |
| Favorable | 5 (5) |
| Intermediate-I | 27 (28) |
| Intermediate-II | 12 (13) |
| Adverse | 27 (28) |
| Not known | 24 (25) |
| Type of cytogenetic abnormality | |
| t(8;21) | 3 (3) |
| CN-AML | 30 (32) |
| FLT3-ITD | 6 (20) |
| FLT3-TKD | 3 (10) |
| NPM1 | 5 (17) |
| Unknown | 7 (23) |
| CK-AML | 15 (16) |
| del(5q) | 4 (4) |
| +8 | 4 (4) |
| −7 | 3 (3) |
| Other abnormalities | 11 (12) |
| Karyotype failure | 2 (2) |
| Unknown | 12 (13) |
| Characteristics . | Value: n, median (range), or n (%) . |
|---|---|
| Total | n = 95 |
| Age | 70 (24-89) |
| ≥65 y | 61 (64) |
| ≥75 y | 31 (33) |
| Sex | |
| Female | 40 (42) |
| Male | 55 (58) |
| Ethnic origin | |
| Asian | 1 (1) |
| Black or African American | 5 (5) |
| Caucasian | 88 (92) |
| Not reported | 1 (1) |
| Prior AML therapies | 3 (0-8) |
| 1 | 17 (18) |
| 2 | 19 (20) |
| 3 | 22 (23) |
| ≥4 | 30 (32) |
| 0* | 7 (7) |
| ECOG performance status | |
| 0 | 26 (27) |
| 1 | 69 (73) |
| ELN classification | |
| Favorable | 5 (5) |
| Intermediate-I | 27 (28) |
| Intermediate-II | 12 (13) |
| Adverse | 27 (28) |
| Not known | 24 (25) |
| Type of cytogenetic abnormality | |
| t(8;21) | 3 (3) |
| CN-AML | 30 (32) |
| FLT3-ITD | 6 (20) |
| FLT3-TKD | 3 (10) |
| NPM1 | 5 (17) |
| Unknown | 7 (23) |
| CK-AML | 15 (16) |
| del(5q) | 4 (4) |
| +8 | 4 (4) |
| −7 | 3 (3) |
| Other abnormalities | 11 (12) |
| Karyotype failure | 2 (2) |
| Unknown | 12 (13) |
CK-AML, complex karyotype AML; CN-AML, cytogenetically normal AML; ELN, European LeukemiaNet.
Poor risk, untreated elderly patients with AML or MDS.